Favorable Press Coverage Somewhat Unlikely to Impact CounterPath (CPAH) Stock Price

Media stories about CounterPath (NASDAQ:CPAH) (TSE:CCV) have been trending positive recently, Accern reports. Accern ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. CounterPath earned a media sentiment score of 0.34 on Accern’s scale. Accern also assigned headlines about the software maker an impact score of 45.8215512851525 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

CounterPath (NASDAQ:CPAH) traded up $0.01 during mid-day trading on Monday, reaching $2.89. The company’s stock had a trading volume of 1,378 shares, compared to its average volume of 142,179. CounterPath has a 1-year low of $1.75 and a 1-year high of $7.30. The company has a market cap of $17.09, a P/E ratio of -5.78 and a beta of -0.12.

How to Become a New Pot Stock Millionaire

Several research analysts have weighed in on CPAH shares. Zacks Investment Research upgraded CounterPath from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a research note on Monday, December 18th. ValuEngine downgraded CounterPath from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st.

In other CounterPath news, Director Steven Bruk purchased 20,000 shares of the company’s stock in a transaction on Monday, March 19th. The stock was acquired at an average cost of $3.67 per share, for a total transaction of $73,400.00. Following the purchase, the director now directly owns 58,647 shares of the company’s stock, valued at approximately $215,234.49. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders acquired a total of 154,000 shares of company stock valued at $603,630 over the last 90 days. 38.30% of the stock is currently owned by corporate insiders.

WARNING: “Favorable Press Coverage Somewhat Unlikely to Impact CounterPath (CPAH) Stock Price” was originally posted by Ticker Report and is the property of of Ticker Report. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright law. The original version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3302535/favorable-press-coverage-somewhat-unlikely-to-impact-counterpath-cpah-stock-price.html.

CounterPath Company Profile

CounterPath Corporation designs, develops and sells software and services that enable enterprises and telecommunication service providers to deliver unified communications (UC) services, including voice, video, messaging and collaboration functionality, over their Internet Protocol (IP)-based networks.

Insider Buying and Selling by Quarter for CounterPath (NASDAQ:CPAH)

Receive News & Ratings for CounterPath Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CounterPath and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Zacks: Analysts Anticipate PennantPark Investment Co.  Will Post Quarterly Sales of $27.23 Million
Zacks: Analysts Anticipate PennantPark Investment Co. Will Post Quarterly Sales of $27.23 Million
RSP Permian  Given a $69.00 Price Target by Stephens Analysts
RSP Permian Given a $69.00 Price Target by Stephens Analysts
Sandler O’Neill Analysts Give Simmons First National  a $35.00 Price Target
Sandler O’Neill Analysts Give Simmons First National a $35.00 Price Target
Wells Fargo Downgrades Emergent BioSolutions  to Market Perform
Wells Fargo Downgrades Emergent BioSolutions to Market Perform
Targa Resources  PT Set at $53.00 by Seaport Global Securities
Targa Resources PT Set at $53.00 by Seaport Global Securities
Cognex  Raised to Buy at Zacks Investment Research
Cognex Raised to Buy at Zacks Investment Research


© 2006-2018 Ticker Report. Google+.